We then evaluated seven cohorts of different cancer types treated with PD-1 or PD-L1 immune-checkpoint antagonists, and the MSC scores of tumor samples from each cohort were quantified and patients were divided into the high and low MSC score groups according to a median cut-off value. The gene discussed is CD274; the disease is cancer.